Genmab kept at neutral by Merrill

Merrill Lynch analyst Erica Whittaker rated Genmab at neutral on the company's lower-than-expected third-quarter loss. Genmab's revenues were 31% higher than the analyst's expectations. The company retained its guidance for 2006 of a Dkr 490 to Dkr 530 million operating loss and net loss in the range of Dkr 440 to Dkr 480 million. Shares of the Copenhagen biotechnology company were up Dkr 3.00, or 1.15%, at Dkr 264.00. (Copenhagen: GEN)

© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere. For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.